• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Influence of obesity on sulfonamide disposition in Zucker rats.

作者信息

Kaul S, Ritschel W A

机构信息

Division of Pharmaceutics, University of Cincinnati Medical Center, College of Pharmacy, Ohio 45267.

出版信息

Eur J Drug Metab Pharmacokinet. 1988 Oct-Dec;13(4):273-83. doi: 10.1007/BF03190091.

DOI:10.1007/BF03190091
PMID:3243323
Abstract

The genetically obese Zucker rat was used as a model of obesity and compared to its lean littermate to assess and quantify obesity-altered changes in the in vivo disposition of six sulfonamides. Body composition determination indicated that the obese rats were twice the weight of lean rats and a distinct trend towards an increase in fat free mass and total body water was observed. The sulfonamide blood concentration was measured by colorimetry after a 7 mg/kg intravenous dose. All sulfonamides exhibited a biexponential decline of blood concentration with time. The volume of distribution and clearance of sulfanilamide in lean and obese rats were similar resulting in similar elimination half-lives. A decrease in clearance coupled with a trend towards an increase in volume of distribution prolonged the elimination half-life of sulfadiazine in obese rats. For sulfapyridine, sulfamerazine, sulfisomidine and sulfisoxazole, increases in the volumes of distribution and clearances resulted in similar elimination half-lives in lean and obese rats. The free fractions of the sulfonamides were significantly increased in the serum of obese rats, the influence of which on the volume of distribution and clearance is discussed.

摘要

相似文献

1
Influence of obesity on sulfonamide disposition in Zucker rats.
Eur J Drug Metab Pharmacokinet. 1988 Oct-Dec;13(4):273-83. doi: 10.1007/BF03190091.
2
Free fatty acids and the binding of sulfonamides in the serum of genetically obese Zucker rat.遗传性肥胖 Zucker 大鼠血清中游离脂肪酸与磺胺类药物的结合
Methods Find Exp Clin Pharmacol. 1987 May;9(5):317-20.
3
Disposition and toxicity of amphotericin-B in the hyperlipidemic Zucker rat model.两性霉素B在高脂血症Zucker大鼠模型中的处置与毒性
Int J Obes. 1990 Jun;14(6):465-72.
4
Phenobarbital in the genetically obese Zucker rat. I. Pharmacokinetics after acute and chronic administration.苯巴比妥在遗传性肥胖的 Zucker 大鼠中的研究。I. 急性和慢性给药后的药代动力学。
J Pharmacol Exp Ther. 1984 Dec;231(3):649-53.
5
Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats.(±)-维拉帕米在瘦型和肥胖型 Zucker 大鼠体内的药代动力学和动力学
J Pharmacol Exp Ther. 1986 Aug;238(2):642-7.
6
Quantitative structure--pharmacokinetic relationship of a series of sulfonamides in the rat.大鼠体内一系列磺胺类药物的定量构效关系。
Eur J Drug Metab Pharmacokinet. 1990 Jul-Sep;15(3):211-7. doi: 10.1007/BF03190206.
7
Disposition of D-fenfluramine in lean and obese rats.右旋芬氟拉明在瘦型和肥胖型大鼠体内的处置情况。
Appetite. 1988 Feb;10(1):45-55. doi: 10.1016/s0195-6663(88)80032-1.
8
The metabolic clearance rate of corticosterone in lean and obese male Zucker rats.瘦型和肥胖型雄性 Zucker 大鼠中皮质酮的代谢清除率。
Metabolism. 1989 Jun;38(6):530-6. doi: 10.1016/0026-0495(89)90212-6.
9
Pharmacokinetic characteristics of the obese overfed rat.肥胖过度喂养大鼠的药代动力学特征。
Int J Obes. 1989;13(1):69-79.
10
Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and sprague-dawley rats: implications of decreased glucuronidation in obese Zucker rats.过氧化物酶体增殖物激活受体激动剂在遗传性肥胖的 Zucker 大鼠和 Sprague-Dawley 大鼠体内的药代动力学差异:肥胖 Zucker 大鼠葡萄糖醛酸化降低的影响
Drug Metab Dispos. 2004 Sep;32(9):909-14.

引用本文的文献

1
Cloning, expression, purification and characterization of human mitochondrial carbonic anhydrase VA.人线粒体碳酸酐酶VA的克隆、表达、纯化及特性分析
3 Biotech. 2016 Jun;6(1):16. doi: 10.1007/s13205-015-0334-1. Epub 2016 Jan 7.
2
Quantitative structure--pharmacokinetic relationship of a series of sulfonamides in the rat.大鼠体内一系列磺胺类药物的定量构效关系。
Eur J Drug Metab Pharmacokinet. 1990 Jul-Sep;15(3):211-7. doi: 10.1007/BF03190206.

本文引用的文献

1
Distribution of 3,4-dimethyl-5-sulfanilamidoisoazole in the body.3,4-二甲基-5-磺胺异恶唑在体内的分布
Proc Soc Exp Biol Med. 1948 Jul-Aug;68(3):472. doi: 10.3181/00379727-68-16520.
2
ALTERATION OF THE ACETYLATION OF SULFONAMIDES BY PROTEIN BINDING, SULFINPYRAZONE, AND SURAMIN.蛋白质结合、磺吡酮和苏拉明对磺胺类药物乙酰化作用的改变
Can J Physiol Pharmacol. 1964 Nov;42:809-17. doi: 10.1139/y64-091.
3
Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity.极度肥胖患者的血容量、心输出量及体循环血流分布
Cardiovasc Res Cent Bull. 1962;1:39-44.
4
Estimation of total body water (virtual tritium space) in the rat, cat, rabbit, guinea-pig and man, and of the biological half-life of tritium in man.大鼠、猫、兔、豚鼠和人体中总体水(虚拟氚空间)的估计以及人体中氚的生物半衰期的估计。
J Physiol. 1960 Nov;154(1):169-76. doi: 10.1113/jphysiol.1960.sp006571.
5
Density of body fat in man and other mammals.人类及其他哺乳动物体内脂肪的密度。
J Appl Physiol. 1953 Oct;6(4):252-6. doi: 10.1152/jappl.1953.6.4.252.
6
Effect of serum protein binding on pharmacokinetics and anticoagulant activity of phenprocoumon in rats.血清蛋白结合对苯丙香豆素在大鼠体内药代动力学及抗凝活性的影响。
J Pharmacokinet Biopharm. 1980 Apr;8(2):177-91. doi: 10.1007/BF01065192.
7
Increased glomerular filtration rate and adrenocortical function in obese women.肥胖女性肾小球滤过率和肾上腺皮质功能增加。
Int J Obes. 1980;4(1):57-63.
8
In vitro hepatic drug metabolism and microsomal enzyme induction in genetically obese rats.遗传性肥胖大鼠的体外肝脏药物代谢及微粒体酶诱导作用
Biochem Pharmacol. 1980 Feb;29(3):289-96. doi: 10.1016/0006-2952(80)90502-x.
9
Surgically affected sulfisoxazole pharmacokinetics in the morbidly obese.手术对病态肥胖患者中磺胺异恶唑药代动力学的影响。
Biopharm Drug Dispos. 1981 Oct-Dec;2(4):329-65. doi: 10.1002/bdd.2510020405.
10
Pharmacokinetic concepts - drug binding, apparent volume of distribution and clearance.药代动力学概念——药物结合、表观分布容积和清除率。
Eur J Clin Pharmacol. 1981;20(4):299-305. doi: 10.1007/BF00618781.